〔Abstract〕 Objective To study the therapeutic effect of piperacillin tazobactam combined with levofloxacin in patients with bronchiectasis. Methods A total of 80 patients with bronchiectasis from Ganxian District People's Hospital of Ganzhou City from June 2021 to April 2023 were selected and divided into control group and observation group by random number table method, with 40 cases in each group. The control group was treated with levofloxacin, and the observation group was treated with piperacillin tazobactam on the basis of the control group, and the therapeutic effects of the two groups were compared. Results The duration of clinical symptoms in the observation group was shorter than that in the control group, the difference was statistically significant (P < 0.05). After treatment, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), maximal voluntary ventilation (MVV) and FEV1/FVC in the observation group were higher than those in the control group, with statistical significance (P < 0.05). After treatment, white blood cells (WBC), neutrophil (NEUT), C-reactive protein (CRP), interleukin-6 (IL-6), erythrocyte sedimentation rate (ESR) and procalcitonin (PCT) in the observation group were lower than those in the control group, with statistical significance (P < 0.05). Conclusion Piperacillin tazobactam combined with levofloxacin can effectively shorten the duration of clinical symptoms, improve lung function and reduce the level of inflammatory factors in patients with bronchiectasis.